All In Biotech

Drug Trial Radar · NCT07734415

Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

A Long-term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous IMG-007 in Participants of a Previous IMG-007 Moderate-To-Severe Atopic Dermatitis Clinical Trial

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

400

Planned (sponsor's estimate)

Start

Jun 5, 2026

Primary completion

Mar 2028

Study completion Mar 2028

Sponsor

Lead sponsor
Inmagene LLCIndustry
Sponsor type
Industry
First posted
Jul 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)

Conditions

  • Atopic Dermatitis
  • Atopic Dermatitis Eczema
  • Eczema

Interventions

  • IMG-007Drug

    Participants will receive IMG-007 subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitisTime frame: Baseline, Week 44

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • Inmagene Site 1

    Lancaster, California

  • Inmagene Site 23

    Los Angeles, California

  • Inmagene Site 19

    Ocala, Florida

  • Inmagene Site 4

    Tampa, Florida

  • Inmagene Site 2

    Rolling Meadows, Illinois

  • Inmagene Site 6

    Kew Gardens, New York

  • Inmagene Site 21

    New York, New York

  • Inmagene Site 11

    Woodbury, New York

  • Inmagene Site 20

    Charlotte, North Carolina

  • Inmagene Site 10

    Fargo, North Dakota

  • Inmagene Site 9

    Columbus, Ohio

  • Inmagene Site 5

    Mayfield Heights, Ohio

  • Inmagene Site 3

    Portland, Oregon

  • Inmagene Site 12

    Anderson, South Carolina

  • Inmagene Site 8

    Southlake, Texas

  • Inmagene Site 7

    Burien, Washington

  • Inmagene Site 15

    Surrey, British Columbia, Canada

  • Inmagene Site 22

    Vancouver, British Columbia, Canada

  • Inmagene Site 17

    Greater Sudbury, Ontario, Canada

  • Inmagene Site 13

    Mississauga, Ontario, Canada

  • Inmagene Site 18

    North Bay, Ontario, Canada

  • Inmagene Site 14

    Montreal, Quebec, Canada

  • Inmagene Site 16

    Saskatoon, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.